Results 151 to 160 of about 92,917 (279)

Synergistic associations of metformin and GLP‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 946-959, February 2026.
Abstract Background Metformin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) may reduce the risk of adiposity‐related cancers in patients with type 2 diabetes (T2D). The potential synergistic effects of these treatments on cancer incidence remain unclear, considering their distinct biological mechanisms and their associated effects on body ...
Alex E. Henney   +6 more
wiley   +1 more source

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers

open access: yesEuropean Journal of Haematology, Volume 116, Issue 2, Page 174-184, February 2026.
ABSTRACT BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non‐trial settings. We conducted a real‐life study in secondary and tertiary cancer centers to evaluate the PFS in 18–59 years aged ...
Marco Picardi   +28 more
wiley   +1 more source

Lymph node ratio has greater prognostic value than positive lymph node count in papillary renal cell carcinoma [PDF]

open access: green, 2023
Lun Zhao   +7 more
openalex   +1 more source

Emerging Role of ctDNA Fragmentomics and Epigenetic Signatures in the Early Detection, Minimal Residual Disease Assessment, and Precision Monitoring of Renal Cell Carcinoma

open access: yesJournal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Renal cell carcinoma (RCC) presents a significant global health challenge, with a substantial proportion of patients diagnosed with advanced or metastatic disease due to the limitations of current diagnostic imaging and the lack of validated non‐invasive biomarkers.
Hossam Kamli, Najeeb Ullah Khan
wiley   +1 more source

Clinical significance and immune microenvironment association of cuproptosis‐related genes in pan‐cancer

open access: yesExperimental Physiology, Volume 111, Issue 2, Page 539-555, 1 February 2026.
Abstract Recent studies highlight the important roles of cuproptosis in cancer cells. However, the roles of the cuproptosis‐related genes (CRGs) in different cancers are still not fully understood. Comprehensive analysis was performed using open‐source bioinformatic platforms to disclose the expression profiles, prognostic significance, genomic and ...
Xinyu Ge   +10 more
wiley   +1 more source

CLEAR CELL-PAPILLARY RENAL CELL CARCINOMA

open access: yesPathology, 2014
Clear cell papillary renal cell carcinoma (CCPRCC) is renal neoplasm that has been recently proposed to be added to the current WHO classification of renal tumors. We collected and described a series of these neoplasms, in order to get insights to their clinico-pathological and molecular profiles. We identified 14 CCPRCC.
openaire   +3 more sources

Unilateral Multifocal Type 2 Papillary Renal Cell Carcinoma in Adolescence. A Case Report [PDF]

open access: hybrid, 2019
Sol Yoon   +9 more
openalex   +1 more source

Atraumatic Ruptured Giant Renal Tumor

open access: yesThe Annals of African Surgery, 2020
Massive hemoperitoneum due to spontaneous rupture of renal cell carcinoma is a rare presentation during emergency laparotomy. A 60-year-old female patient presented with severe abdominal pain, nausea, vomiting and abdominal distension.
Gezahen Negusse Ayane, Khutsafalo Kadimo
doaj  

Papillary renal cell carcinoma with malakoplakia: A unique case

open access: gold, 2022
Abigail A. Roth   +4 more
openalex   +1 more source

Renal cell carcinoma in Iceland [PDF]

open access: yes, 2007
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/OpenRenal Cell Carcinoma (RCC) is by far the most common malignant tumor of the kidney.
Guðmundur Vikar Einarsson   +2 more
core  

Home - About - Disclaimer - Privacy